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Interrelationships Between Serum 25-
Hydroxycalciferol and Bone Mass in Adults on 
Long-Term Antiepileptic Drug Therapy 
*K.-H. Krause, *P. Berlit, and **H. Schmidt-Gayk 
*N eurologische Universitätsklinik and ** Chirurgische Universitätsklinik, 
D-6900 Heidelberg, Federal Republic of Germany 
Using photon absorptiometry, which seems to be a better 
diagnostic instrument for detecting osteomalacia than x-ray 
examination ( 3 ) , several investigators found a decrease of bone 
mass i n e p i l e p t i c s on chronic a n t i e p i l e p t i c drug therapy (4, 7, 
9, 10). A n t i e p i l e p t i c drug induced osteomalacia has been 
explained by a disturbance of vitamin D metabolism ( 1 , 5, 6, 8, 
19), which leads to a lowering of 25-hydroxycalciferol 
concentrations i n the serum of chronically treated e p i l e p t i c s . 
As yet the diagnostic value of serum 25-hydroxycalciferol levels 
i n detecting a n t i e p i l e p t i c drug induced osteomalacia remains 
unclear. The aim of the present study was to evaluate possible 
relationships between serum 25-hydroxycalciferol concentrations 
and bone mass i n adult e p i l e p t i c s on chronic a n t i e p i l e p t i c drug 
therapy. 
PATIENTS AND METHODS 
277 e p i l e p t i c outpatients (157 males, 120 females), aged 20 to 
40 years, treated with a n t i e p i l e p t i c drugs for at least one year 
and taking no vitamin D supplement, were examined between 
December 1980 and July 1981. Most patients received combination 
therapy. The average dai l y intake of a n t i e p i l e p t i c drugs was 
calculated i n equivalent u n i t s per day (1 equivalent u n i t = 50mg 
Phenytoin, 30mg phenobarbital, 125mg primidone, 50mg CHP-pheno-
b a r b i t a l , 200mg carbamazepine, 50mg mephenytoin, 250mg ethosuxi-
mide, 300mg sodium valproate, 2mg clonazepam, 300mg methsuximide, 
100mg sulthiame, 250mg trimethadione). 20 patients (13 males, 
7 females) were taking phenytoin i n monotherapy, 47 (26 males, 21 
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females) primidone, 30 (12 males, 18 females) carbamazepine, and 
20 (11 males, 9 females) sodium valproate. Bone mass was 
measured i n each patient at the midshaft of the radius of the 
r i g h t arm using a Norland-Cameron Bone Mineral Analyzer (Norland 
Instrument Company, Fort Atkinson, Wisconsin). Serum 25-hydroxy 
c a l c i f e r o l concentrations were determined by a radioassay i n a 
modification of the method described by Belsey et al (2) ; 25-
hydroxycalciferol standards were prepared i n vitamin D-deficient 
charcoal treated serum instead of ethanol as described by the 
authors. The s t a t i s t i c a l comparison of bone mass and serum 25-
hydroxycalciferol employed li n e a r regression analysis. Variance 
analysis of bone mass values i n patients undergoing monotherapy 
was carried out. Furthermore, a l i n e a r regression analysis was 
performed for the bone mass and the average dai l y intake of a n t i -
e p i l e p t i c drugs. The patients were divided i n t o three groups 
according to the duration of therapy : 1 to 3, 4 to 10 and over 
10 years of treatment. Bone mass values as well as 25-hydroxy-
c a l c i f e r o l levels of these groups were compared by variance 
analysis, considering sex differences i n bone mass and seasonal 
differences i n 25-hydroxycalciferol levels. 
RESULTS 
The bone mass (mean ± SD) was 0.82 ± 0.08g cm - 2 i n the males 
and 0.72 ± 0.07g cm - 2 i n the females. The serum 25-hydroxy-
c a l c i f e r o l concentration (mean ± SD) was 73.1 ± 68.2 nmol /1 i n 
the males and 72.7 ± 70.7 nmol /1 i n the females. There was no 
s i g n i f i c a n t c o r r e l a t i o n between these parameters ( c o r r e l a t i o n 
c o e f f i c i e n t R = - 0.047 i n males and R = 0.027 i n females). For 
both sexes, serum 25-hydroxycalciferol levels were c l e a r l y higher 
i n the summer months (Fig. 1). Therefore, a regression analysis 
between bone mass and 25-hydroxycalciferol was carried out for 
each month. The re s u l t s are shown i n Table 1 ; no s i g n i f i c a n t 
c o r r e l a t i o n was found. 
25.4% (n = 40) of the males had a lowered bone mass<0.76g cm - 2 
whereas 20.8% (n = 25) of the females had lowered values 
<0.67g cm - 2. The mean serum 25-hydroxycalciferol levels i n 
these patients were higher than i n the whole e p i l e p t i c population 
(82.4 ± 74.8 nmol /1 i n males and 79.0 ± 62.4 nmol /1 i n females). 
The values of bone mass and 25-hydroxycalciferol i n r e l a t i o n to 
duration of therapy are given i n Table 2. The 25-hydroxy-
c a l c i f e r o l concentrations were higher i n patients treated for up 
to 3 years compared with the other groups, as well i n the summer 
months, but there were no s i g n i f i c a n t differences. The duration 
of therapy had no influence on the mean values of bone mass, but 
the percentage of patients with lowered bone mass i n the groups 
treated for 1 to 3 and over 10 years was higher than i n those 
treated for 4 to 10 years (Fig. 2). However, the number of 
affected e p i l e p t i c s i n each group was too small for s t a t i s t i c a l 
evaluation. No rel a t i o n s h i p was found between the bone mass 
and the average dai l y intake of a n t i e p i l e p t i c drugs, neither i n 
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TABLE 1, Correlation c o e f f i c i e n t s of regression analysis of 
bone mass and 25-hydroxycalciferol for each month 
December 
January 
February 
March 
A p r i l 
May 
June 
July 
Males 
R 
- 0.0358 
+ 0.0209 
- 0.0896 
- 0.2062 
- 0.1792 
- 0.0748 
+ 0.5421 
+ 0.0282 
Females 
R 
- 0.3260 
+ 0.0248 
- 0.2851 
- 0.2049 
+ 0.0936 
+ 0.0574 
+ 0.3758 
+ 0.2799 
TABLE 2. 
Bone mass 
(g cm"2) 
Bone mass and serum 25-hydroxycalciferol levels 
(mean ± SD) i n r e l a t i o n to duration of a n t i e p i l e p t i c 
drug therapy 
Duration of treatment 
1-3 years 4-10 years 10 years 
0.81 ± 0.08 0.80 ± 0.06 0.82 ± 0.08 
(n = 24) (n = 46) (n = 87) 
0.71 ± 0.06 0.72 ± 0.06 0.71 ± 0.08 
(n = 24) (n = 26) (n = 70) 
males 
females 
25-hydroxy-
c a l c i f e r o l 
(nmol/1) 
both sexes 
December 58.7 ± 59.9 54.4 ± 63.8 49.9 ± 60.1 
to A p r i l (n = 29) (n = 51) (n = 96) 
May to 132.3 ± 86.1 90.1 ± 72.6 112.4 ± 64.8 
July (n = 19) (n = 21) (n = 61) 
ON 
hydroxycalciferol 
200-
100-
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n=18 
n=13 
n=28 
n=18 
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FIG. 1. Seasonal differences of serum 25-hydroxycalciferol l e v e l s i n nmol/1 (mean + SD) 
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30 
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n = 6 
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(<0.76 g c m " 2 ) 
females with lowered bone mass 
(<0.67g c m - 2 ) 
U -10 >10 duration of 
anticonvulsant 
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FIG. 2. Percentage of e p i l e p t i c s with lowered bone mass i n 
r e l a t i o n to the duration of a n t i e p i l e p t i c drug therapy 
males ( c o r r e l a t i o n c o e f f i c i e n t R = 0.0487) nor i n females (R = 
- 0.1286). The values of bone mass i n e p i l e p t i c s on monotherapy 
are given i n Table 3 ; no s i g n i f i c a n t differences were found. 
TABLE 3. Values of bone mass (mean ± SD) i n patients on 
monotherapy 
Phenytoin 13 
primidone 26 
carbamazepine 12 
sodium valproate 11 
Males 
bone mass 
(g cm"2) 
0.82 ± 0.06 
0.83 ± 0.08 
0.82 ± 0.09 
0.82 ± 0.07 
7 
21 
18 
9 
F emales 
bone mass 
(g cm - 2) 
0.72 ± 0.03 
0.72 ± 0.07 
0.74 ± 0.10 
0.72 ± 0.05 
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DISCUSSION 
Our data indicate that there i s no re l a t i o n s h i p between serum 
25-hydroxycalciferol concentrations and the state of bone 
mineralisation. Even i f the seasonal v a r i a t i o n of 25-hydroxy-
c a l c i f e r o l , which was much more marked i n our study than i n that 
of Offerman et a l (15), i s taken i n t o consideration, there was no 
co r r e l a t i o n between bone mass and serum 25-hydroxycalciferol. 
These findings are i n accordance with the re s u l t s of Pylypchuk et 
a l (16) and Mosekilde et a l (12, 13). The l a t t e r authors 
correlated q u a n t i t a t i v e morphometric data of i l i a c crest biopsies 
with serum 25-hydroxycalciferol levels i n e p i l e p t i c s and found no 
relationships either (12). According to t h e i r histopathological 
findings the authors suspected a difference between a n t i e p i l e p t i c 
drug induced osteomalacia and osteomalacia induced by vitamin D 
deficiency (13). I t might be possible t h a t , not only 
disturbances of vitamin D metabolism, but also a d i r e c t 
i n h i b i t i o n of membrane uptake of calcium or i n h i b i t i o n of bone 
resorption may play a role i n developing drug induced osteo-
malacia ( 1 , 17, 18). For p r a c t i c a l purposes i t i s noteworthy 
that the determination of serum 25-hydroxycalciferol levels i s 
obviously not a suitable instrument for detecting a n t i e p i l e p t i c 
drug induced osteomalacia. 
Surprisingly we found no rel a t i o n s h i p between bone mass and 
dose of a n t i e p i l e p t i c drugs. This fact i s i n contrast to the 
findings of Christiansen et a l (4) and to own re s u l t s i n a r e t r o -
spective study with 837 e p i l e p t i c s (11), who had been 
investigated by X-ray. Probably t h i s difference i s due to the 
kind of cal c u l a t i o n of the average d a i l y drug dose. In those 
patients with an intake of a n t i e p i l e p t i c drugs since early c h i l d -
hood the na t u r a l l y low dai l y dose i n t h i s age decreases the 
average d a i l y intake of the whole duration of treatment - despite 
the high doses at the time of examination. 
In accordance with the re s u l t s of Hahn et a l (7) and i n 
contrast to those of Christiansen et a l ( 4 ) , i n the present study 
there was no general influence of duration of therapy on bone 
mass values, but abnormalities were more common i n the f i r s t 3 
years of therapy and i n patients receiving a n t i e p i l e p t i c drugs 
for more than 10 years, than i n the i n t e r v a l between. We had 
simi l a r r e s u l t s i n our previous study, mentioned above (11). 
One may guess that there i s a disturbance of bone metabolism i n 
some patients soon a f t e r the beginning of therapy, followed by a 
tendency to normalisation as an expression of an adaption process. 
The group of patients treated for more than 10 years again showed 
a higher incidence of lowered bone mass ; t h i s may be caused by 
the fact that there are many e p i l e p t i c s i n t h i s group who 
received medication since childhood, when bone metabolism i s more 
susceptible to drug treatment. The r e l a t i o n of a n t i e p i l e p t i c 
drug induced osteomalacia to duration of therapy seems to be of 
special i n t e r e s t for long term prospective investigations. 
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We found no s i g n i f i c a n t differences i n bone mass between the 
patient groups, treated with four major a n t i e p i l e p t i c drugs as 
monotherapy. S i m i l a r l y , Christiansen et a l (4) found comparable 
patterns of bone mineral content i n patients treated with 
Phenytoin and primidone as monotherapy as well as i n combination. 
Recently biochemical evidence of a disturbance i n bone metabolism 
under monotherapy with carbamazepine has been presented (14). 
However, to our knowledge, sodium valproate as monotherapy has 
not been incriminated i n producing these changes. 
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